TWD 17.1
(-0.87%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 48.64 Million TWD | -16.56% |
2022 | 58.3 Million TWD | 136.9% |
2021 | 24.61 Million TWD | -88.2% |
2020 | 208.6 Million TWD | 156.13% |
2019 | 81.44 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 44.36 Million TWD | -8.8% |
2024 Q2 | 44.36 Million TWD | 0.0% |
2023 FY | 48.64 Million TWD | -16.56% |
2023 Q2 | 30.85 Million TWD | 0.0% |
2023 Q1 | 30.85 Million TWD | -47.08% |
2023 Q3 | 48.64 Million TWD | 57.66% |
2023 Q4 | 48.64 Million TWD | 0.0% |
2022 Q3 | 58.3 Million TWD | 0.0% |
2022 Q4 | 58.3 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 94.655% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | 82.781% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 91.754% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 98.556% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 98.659% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 99.268% |
Center Laboratories, Inc. | 6.78 Billion TWD | 99.283% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | 69.793% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 94.547% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | 84.844% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 89.712% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 93.648% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 92.114% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | 82.68% |
UniPharma Co., Ltd. | 37.4 Million TWD | -30.074% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 95.209% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | 36.063% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | 86.988% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | 2.156% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | 55.266% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | 63.593% |